Saiz-Rodriguez M, Almenara S, Navares-Gomez M, Ochoa D, Roman M, Zubiaur P
Biomedicines. 2020; 8(4).
PMID: 32331352
PMC: 7235792.
DOI: 10.3390/biomedicines8040094.
Filgueira G, Filgueira O, Carvalho D, Marques M, Moises E, Duarte G
Br J Clin Pharmacol. 2017; 83(7):1571-1579.
PMID: 28042936
PMC: 5465346.
DOI: 10.1111/bcp.13226.
Moises E, de Barros Duarte L, de Carvalho Cavalli R, Carvalho D, Filgueira G, Marques M
Reprod Sci. 2015; 22(7):791-7.
PMID: 25563756
PMC: 4565472.
DOI: 10.1177/1933719114561560.
Chen M
Clin Pharmacokinet. 2006; 45(10):957-64.
PMID: 16984210
DOI: 10.2165/00003088-200645100-00001.
Rais N, Chawla Y, Kohli K
Eur J Clin Pharmacol. 2006; 62(6):417-22.
PMID: 16758258
DOI: 10.1007/s00228-006-0105-3.
The distribution and gender difference of CYP3A activity in Chinese subjects.
Zhu B, Liu Z, Chen G, Chen X, Ou-Yang D, Wang L
Br J Clin Pharmacol. 2003; 55(3):264-9.
PMID: 12630976
PMC: 1884221.
DOI: 10.1046/j.1365-2125.2003.01728.x.
Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Muck W, Unger S, Kawano K, Ahr G
Br J Clin Pharmacol. 1998; 45(6):583-90.
PMID: 9663814
PMC: 1873645.
DOI: 10.1046/j.1365-2125.1998.00717.x.
Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers.
Rawashdeh N, Battah A, Irshaid Y
Eur J Drug Metab Pharmacokinet. 1997; 22(3):259-64.
PMID: 9358208
DOI: 10.1007/BF03189816.
Factors affecting the absolute bioavailability of nifedipine.
Rashid T, Martin U, Clarke H, Waller D, Renwick A, George C
Br J Clin Pharmacol. 1995; 40(1):51-8.
PMID: 8527268
PMC: 1365027.
DOI: 10.1111/j.1365-2125.1995.tb04534.x.
Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.
Soons P, Mulders T, Uchida E, Schoemaker H, Cohen A, Breimer D
Eur J Clin Pharmacol. 1993; 44(2):163-9.
PMID: 8453961
DOI: 10.1007/BF00315475.
Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure.
Kierdorf H, Muller A, Blanke P, GELLERT J, Heintz B, Ramsch K
Eur J Clin Pharmacol. 1993; 45(2):129-34.
PMID: 8223833
DOI: 10.1007/BF00315493.
Pharmacogenetic phenotyping and genotyping. Present status and future potential.
Gonzalez F, Idle J
Clin Pharmacokinet. 1994; 26(1):59-70.
PMID: 8137598
DOI: 10.2165/00003088-199426010-00005.
Clinical significance of genetic influences on cardiovascular drug metabolism.
Arcavi L, Benowitz N
Cardiovasc Drugs Ther. 1993; 7(3):311-24.
PMID: 8103355
DOI: 10.1007/BF00880154.
Assessment of liver metabolic function. Clinical implications.
Brockmoller J, Roots I
Clin Pharmacokinet. 1994; 27(3):216-48.
PMID: 7988103
DOI: 10.2165/00003088-199427030-00005.
Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.
Brogden R, Sorkin E
Drugs. 1995; 49(4):618-49.
PMID: 7789292
DOI: 10.2165/00003495-199549040-00009.
Research in the Division of Pharmacology.
Breimer D
Pharm Weekbl Sci. 1985; 7(2):63-6.
PMID: 4000900
DOI: 10.1007/BF02106129.
Proceedings of the British Pharmacological Society. Amsterdam, 2nd-4th July 1986. Abstracts.
Br J Pharmacol. 1986; 89 Suppl:471P-752P.
PMID: 3756375
PMC: 1917135.
The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers.
Lobo J, JACK D, Kendall M
Eur J Clin Pharmacol. 1986; 30(1):57-60.
PMID: 3709633
DOI: 10.1007/BF00614196.
The trans-hepatic extraction of nifedipine.
Challenor V, Waller D, Renwick A, Gruchy B, George C
Br J Clin Pharmacol. 1987; 24(4):473-7.
PMID: 3689628
PMC: 1386309.
DOI: 10.1111/j.1365-2125.1987.tb03200.x.
A comparison of isoxicam pharmacokinetics in young and elderly subjects.
George C, Renwick A, Darragh A, Hosie J, Blake D, van Marle W
Br J Clin Pharmacol. 1986; 22 Suppl 2:129S-134S.
PMID: 3620272
PMC: 1400956.
DOI: 10.1111/j.1365-2125.1986.tb02994.x.
